Treatment
SGLT-2 inhibitor clinical trials
We’re tracking 14 recruiting studies that include SGLT-2 inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT07172971RecruitingPhase 1
SGLT2i drug for heart health in Duchenne muscular dystrophy
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
Nashville, TennesseeAges 8–18 - NCT06753994RecruitingPhase 1
Continuous ketone monitoring in type 1 diabetes with SGLT2 inhibitors
This study tests a new sensor that continuously measures ketone levels in people with type 1 diabetes who are also taking SGLT2 inhibitors. It aims to see if the sensor can help prevent diabetic ketoacidosis.
Montreal, QuebecAges 18 years+ - NCT07070765Recruiting
Study on dapagliflozin to protect the heart during breast cancer chemo
This trial tests if a heart-protecting drug called dapagliflozin can help prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. It may be an option if you have low to medium heart risk factors.
Aberdeen, AberdeenshireAges 18–70 - NCT05029115Enrolling by invitation
SGLT2 pill study for atrial fibrillation with type 2 diabetes
This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.
Yangcheon, SeoulAges 20–80 - NCT07157475Recruiting
Blood vessel complications after leg artery procedures with SGLT2 inhibitors
This study looks at how a type of medicine called SGLT2 inhibitors (used for diabetes, kidney disease, or heart issues) affects blood vessel complications in people who have had a leg procedure to improve blood flow. It compares patients taking the medicine to those who are not.
Wroclaw, Lower Silesian VoivodeshipAges 18 years+ - NCT07143773RecruitingPhase 4
SGLT2i safety in kidney transplant patients without diabetes
This study tests whether a medicine called SGLT2i (a type of pill for kidney health) is safe and helpful for kidney transplant recipients who do not have diabetes. It aims to see if it can improve how the new kidney works.
OdenseAges 18 years+ - NCT06905405Recruiting
Imaging for early heart failure with stiff heart muscle (HFpEF)
This study uses advanced imaging to find early signs of a type of heart failure where the heart pumps well but doesn't relax properly (HFpEF). It may help if you have shortness of breath and a slightly enlarged heart chamber but don't yet have a clear heart failure diagnosis.
Sheffield, South YorkshireAges 18 years+ - NCT04899479RecruitingPhase 4
SGLT-2 inhibitor after heart attack to improve heart recovery
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
SeoulAges 18 years+ - NCT05305911RecruitingPhase 2
SGLT2 drug after first heart attack to reduce heart damage
This Phase 2 trial tests whether an SGLT2 medicine started after a first STEMI heart attack can reduce ongoing heart muscle injury and scarring. It may help people who, based on heart imaging, have larger infarcts and ongoing microvascular damage.
Minneapolis, MinnesotaAges 18–75 - NCT06863532Recruiting
Comparing two add-on treatments for type 2 diabetes
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
Hangzhou, ZhejiangAges 18–74 - NCT07076823RecruitingPhase 1
Canagliflozin for MSI-H colorectal cancer
This trial tests a diabetes drug, canagliflozin, for people with a specific type of colorectal cancer (MSI-H). It's for those whose cancer has continued to grow after at least two standard treatments.
Chengdu, SichuanAges 18–80 - NCT07482020RecruitingPhase 2
SGLT2 inhibitor for atrial fibrillation, high blood pressure, and high blood sugar
This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07572032RecruitingPhase 4
Heart failure recovery after valve or coronary surgery
This study tests when to start two heart-protective medications (ARNI and SGLT2 inhibitors) after you've had surgery to fix a valve problem or blocked heart arteries. Researchers want to see if waiting a bit before starting these drugs helps your heart recover better.
Daegu, DaeguAges 18 years+ - NCT07292909RecruitingPhase 4
Effect of Empagliflozin on Inflammation for Coronary Patients
This trial tests if the diabetes drug empagliflozin can help reduce inflammation in people with stable coronary artery disease who are planning to have a stent placed. It may offer a new way to protect heart health.
Beirut, BeirutAges 18 years+
What SGLT-2 inhibitor is being studied for
Conditions with recruiting SGLT-2 inhibitor studies.
Common questions
- Are there clinical trials studying SGLT-2 inhibitor?
- Yes. Clin2 currently lists 14 recruiting studies that include SGLT-2 inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a SGLT-2 inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is SGLT-2 inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether SGLT-2 inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.